This review positions redox dysregulation – and NOX-dependent signaling in particular – as a unifying mechanism underlying cognitive decline in PD, and discusses emerging therapeutic strategies targeting redox pathways, highlighting NOX modulation as a promising approach to modify the course of Parkinson's disease-associated cognitive impairment.
Abstract
Cognitive dysfunction is one of the most disabling non-motor manifestations of Parkinson's disease (PD), progressing from mild cognitive impairment to Parkinson's disease dementia. Although multiple pathological processes have been individually implicated, the mechanisms linking neurotransmitter deficits, proteinopathies, circuit vulnerability, and neurodegeneration remain insufficiently integrated. Here, we synthesize current evidence on the pathophysiology of cognitive impairment in PD, emphasizing the convergence of dopaminergic, cholinergic, noradrenergic and serotonergic dysfunction with α-synuclein, tau and amyloid-β pathology. We highlight the hippocampus – particularly the CA2 subregion – as a critical anatomical hub connecting synaptic dysfunction, memory impairment, and dementia progression. Accumulating evidence identifies oxidative stress and neuroinflammation as central drivers across these pathological domains. Among endogenous sources of reactive oxygen species, NADPH oxidases (NOX), especially Nox4, emerge as key regulators of redox imbalance, protein aggregation and glial–neuronal interactions. Increased Nox4 activity correlates with hippocampal damage and cognitive decline, whereas experimental inhibition of Nox4 preserves synaptic integrity and improves memory performance in preclinical models. By integrating molecular, cellular and systems-level findings, this review positions redox dysregulation – and NOX-dependent signaling in particular – as a unifying mechanism underlying cognitive decline in PD, and discusses emerging therapeutic strategies targeting redox pathways, highlighting NOX modulation as a promising approach to modify the course of Parkinson's disease-associated cognitive impairment.
Brain aging is a major risk factor for neurodegenerative disorders and is associated with a progressive loss of neuronal homeostasis. Rather than resulting from a single pathological event, brain aging involves coordinated changes across multiple biological processes, including neuroinflammation, proteostasis impairmen...
Hai-Yi Yi, Hai-Meng Qin, J. Goon et al.· International Journal of Mol...· 0 citations
Alzheimer’s disease (AD) is the leading cause of dementia and a heterogeneous neurodegenerative disorder characterized by amyloid-β (Aβ) and tau pathology, impaired proteostasis, neurovascular dysfunction, maladaptive glial and immune responses, and synaptic dysfunction. Human genetic evidence supports an upstream role...
Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder characterized by progressive cognitive decline and complex pathological changes. Cholinergic dysfunction is an early, clinically pivotal feature of AD closely associated with multiple pathological processes, including amyloid-β (Aβ) pathology, neur...
The current understanding of the genetic and physiological mechanisms underlying Alzheimer’s disease is reviewed and modern approaches for diagnosis and treatment are discussed.
Zahraa Mohammed Fakheir, S. A. H. Jasim· Journal of Genetic and Envir...· 0 citations
A “cellular state–pathological network–therapeutic window” framework is proposed and the roles of microglia in amyloid-β plaque seeding and compaction, NLRP3 inflammasome activation, mitochondrial DNA–cGAS–STING signaling, complement-mediated synaptic engulfment, and bidirectional microglia–tau feedback are systematica...
Lian-Jing Xu, Ying Zhang, Li Jiang et al.· Frontiers in Cellular Neuros...· 0 citations
This review proposes conceptualizing Alzheimer's disease as a neural circuit disorder that emerges from sustained crosstalk among multiple interacting pathways, including brain injury, neuroinflammation, mitochondrial and metabolic dysfunction, neurovascular dysfunction, neurovascular dysfunction, synaptic dysfunction,...
Desh Deepak Singh· Current Neuropharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.